Physician profile
Philip E Ferguson
NPI 1437283470
$1,828.46
in general payments reported to CMS, 2019-2025
13 companies · $126 in 2025
The $126 reported for 2025 was more than what a typical Anatomic Pathology & Clinical Pathology provider received nationally (typical 2025 total: $50.59).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.81 · 2022: $36.12 · 2023: $1,588 · 2024: $63.74 · 2025: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $1,500 · Food and Beverage: $278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $1,500.00 |
| Food and Beverage | $277.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $1,500.00 | 2023 | Pyrukynd |
| Merck Sharp & Dohme LLC | $119.93 | 2021-2025 | Keytruda, Welireg, Lynparza |
| G1 Therapeutics, INC. | $50.62 | 2022-2023 | Cosela |
| Janssen Biotech, INC. | $28.23 | 2025 | Rybrevant |
| Pharmacosmos Therapeutics INC. | $23.33 | 2025 | Monoferric |
| Emd Serono, INC. | $20.70 | 2025 | |
| Daiichi Sankyo INC. | $20.42 | 2024 | Enhertu |
| Amgen INC. | $19.38 | 2023 | Lumakras |
| Jazz Pharmaceuticals INC. | $16.11 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.29 | 2023 | Gilotrif |
| Takeda Pharmaceuticals U.S.A., INC. | $14.45 | 2024 | Fruzaqla |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Ferguson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.